Myriad Genetics (MYGN) Tops Q1 EPS by 6c

Myriad Genetics (NASDAQ: MYGN) reported Q1 EPS of $0.41, $0.06 better than the analyst estimate of $0.35. Revenue for the quarter came in at $183.5 million versus the consensus estimate of $177.89 million.

Myriad Genetics sees FY2015 EPS of $1.60-$1.65, versus the consensus of $1.64. Myriad Genetics sees FY2015 revenue of $750-770 million, versus the consensus of $758.3 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• Myriad Genetics (MYGN) Misses Q2 EPS by 19c ; Offers Guidance
• ExxonMobil Q2 profit falls short of forecasts, shares slide
• Dominion Energy (D) Tops Q2 EPS by 4c, Beats on Revenue; Offers FY26 EPS Guidance